Antibody Therapies
Total Trials
8
As Lead Sponsor
As Collaborator
0
Total Enrollment
911
NCT03491709
A Preliminary Clinical Study on the Pharmacokinetics and Safety of CDP1 in Patients With Advanced CRC or HNSCC
Phase: Phase 1
Role: Lead Sponsor
Start: Jul 1, 2018
Completion: Dec 1, 2019
NCT03881787
Clinical Trial to Evaluate Pharmacokinetics,Safety and Immunogenicity of Single Injection of CDP1 to Healthy Volunteers Compared to Erbitux
Start: Feb 27, 2019
Completion: Dec 30, 2019
NCT03908814
Phase I Clinical Trial of Human Anti-PD-L1 Antibody Injection (LDP) in Patients With Advanced Malignant Tumors
Start: Apr 27, 2019
Completion: Apr 26, 2022
NCT04151810
Phase I Clinical Trial of CDP1 in Patients With Advanced Solid Tumors
Start: Dec 16, 2019
Completion: Oct 13, 2022
NCT04718584
the Efficacy and Safety of LDP in Patients With Urinary and Male Genital Tumors
Phase: Phase 2
Start: Sep 11, 2020
Completion: Nov 30, 2023
NCT04739111
An Exploratory Clinical Study of LDP Combined With CDP1 in Patients With Advanced Malignant Tumor
Start: Jan 29, 2021
Completion: Feb 29, 2024
NCT05212896
An Exploratory Clinical Study of BC006 in Patients With Advanced Solid Tumors
Start: Nov 26, 2021
Completion: Dec 31, 2024
NCT06850584
Validation Study of Simplified Chinese Version of LOTCA Scale in the Assessment of Cognitive Impairment in Patients with Traumatic Brain Injury
Phase: N/A
Start: Mar 1, 2025
Completion: Dec 31, 2025
Loading map...